

Figure 1






Figure 2


A



B



C



# Figure 2





Figure 3

A



B





Figure 3

C



D




Figure 3

E

ZFP  
Protein

Vector control  
VZ-573  
VZ-475  
VZ-8  
VZ+42 / +530  
VZ+434a  
VZ+434b  
VZ+472  
VZ+590

F

Relative ZFP mRNA levels  
(VP16 / GAPDH by Taqman)






Figure 4




# Figure 5


A




B



C




D







# Figure 6




# Figure 7



[illegible]

D






FIG. 8

Control

A.



+ ZFP


B.




C.



D.



E.



F.




FIG. 9

# Activation of Human VEGF-A Gene By ZFPs in 293 Cells (VEGF-A protein production detected by ELISA)




Fig. 10

# Activation of Human VEGF-A Gene by ZFPs (VEGF-A mRNA Detected by Taqman Analysis)




Fig. 11

# Activation of Human VEGF-A Gene Promoter by ZFPs (Activation of VEGF Reporter in 293 cells)




Fig. 12



# VEGF Activation By ZFP VOP28A and RAT24A in 293 Cells (VEGF protein detected by ELISA)





FIG. 13

Figure 14


A

VEGF-A mRNA Activation by ZFPs




B

VEGF-C mRNA Activation by ZFPs



# Figure 15



**C**


ZFP Name	Target Sequence 5'-3'	Subsites 5'-3'	Finger Designs
mVZ+57	TGAGCGGGCGGAGGAGc	CGAg GCGg GCGg GCGg GAGg	ASGHLTK F6 ASDELAR F5 ASDELTA F4 ASGSLTR F3 ASDELTA F2 ASDNLAR F1
mVZ+426	GGGGGTGACc	GGGg GGg GAGg	ASCHL3R F3 TSCHLVR F2 DRNLTR F1
mVZ+509	GCTGGGGGCGg	GCTg GGGg GGGg	ASGSLTR F3 ASDLTR F2 DRSHLTR F1

**D**


ZFP	Target	Gel Shift	Apparent Kd (nM)
mVZ+57	TGAGCGGGCGGAGGAGc		0.031
mVZ+426	GGGGGTGACc		<0.01
mVZ+509	GCTGGGGGCGg		<0.01
SP1	GGGGCGGGGg		0.053

Figure 16


**A**



**B**



**C**



Smooth Muscle Cells Infected With  
Adenovirus Expressing VPO 30A




FIG. 17A




FIG. 17B




FIG. 17C




FIG. 17D




FIG. 18




FIG. 18 E

FIG. 19A

GFP



FIG. 19B

MVG





FIG. 19C





VEGF-ZFP (MVG)  
(MVG)

FIG. 20A



GFP Control

FIG. 20B




FIG. 21 A



FIG. 21 B




FIG. 21 C